Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Pacira BioSciences, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-53.8% vs price
Base Case (Median)
20.8% vs price
Bull Case (75th pct.)
23.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $31.20 | 20.8% | High (40%) |
| PE Comparable | $8.03 | -68.9% | Medium (25%) |
| Graham Number | $11.93 | -53.8% | Medium (40%) |
| EV/EBITDA | $31.76 | 23.0% | Medium (20%) |
| EV/FCF | $90.98 | 252.2% | Medium (20%) |
Based on 5 out of 8 methods, PCRX appears fairly valued at the current price of $25.83. The base case fair value of $31.20 implies 20.8% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.
